Medimetriks licenses ozenoxacin, a novel antibacterial, from Ferrer

24 March 2014

US specialty drug firm Medimetriks Pharmaceuticals has entered into a licensing agreement with Ferrer, a privately-held Spanish pharmaceutical company, for the commercialization rights to ozenoxacin, a novel non-fluorinated quinolone antibacterial 1% cream for impetigo, in the USA.

Last year, Ferrer successfully completed the first Phase III Clinical Trial of Ozenoxacin in adult and pediatric patients with impetigo (The Pharma Letter June 5, 2013). The study demonstrated the superiority of ozenoxacin, applied topically twice daily for five days, versus placebo on both the clinical and bacteriological endpoints by the end of therapy. In addition, ozenoxacin demonstrated a superior bacteriological cure compared to placebo, typically by day four. Ozenoxacin was shown to be very well tolerated in both adult and pediatric populations. Development plans include an additional Phase III clinical trial.

In preclinical in vitro and in vivo studies, ozenoxacin has shown excellent antibacterial activity against a broad range of bacteria, including organisms with emerging resistance to other commonly prescribed topical antibiotics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical